Sharescart Research Club logo
Products
Research
Tools
About
ChatGPT Claude Perplexity
Summarize with
ChatGPT Claude Perplexity
Join Channel
Apollo Green₹ 72 (28.6%)ASK Investment₹ 895 (-3.2%)AVPL ₹ 49 (0%)Bootes Impex₹ 775 (-8.8%)CIAL ₹ 442 (-0.5%)CSK ₹ 254 (-3.1%)ESDS Software₹ 478 (2.8%)Garuda Aerospace₹ 468 (-2.1%)Goodluck Defence₹ 385 (16%)Hero Motors₹ 325 (0%)Hinduja Leyland₹ 248 (0%)ICL Fincorp₹ 25 (0%)Incred Holdings₹ 154 (2.7%)Kineco Limited₹ 3285 (0%)Lava ₹ 60 (15.4%)Market Simplified₹ 26 (-7.1%)Matrix Gas₹ 12 (-20%)Motilal Oswal₹ 12.25 (-2%)MSEI ₹ 6.35 (-2.3%)NCDEX ₹ 368 (-1.6%)NSE ₹ 1985 (-2%)Onix Renewable₹ 68 (21.4%)OYO ₹ 23 (-4.2%)OYO Assets₹ 9.25 (-7%)Philips India₹ 1250 (0%)Polymatech Electronics₹ 56 (-3.4%)SBI Mutual₹ 768 (-0.9%)Taparia Tools₹ 6050 (0%)VCI Chemical₹ 64 (0%)Zepto ₹ 40 (-4.8%)

15 Days Price Change

Mankind Pharma IPO

Closing In

  • days
  • Hours
  • Minutes
  • Seconds

WEBSITE Inc. Year: 1991 Industry: Pharmaceuticals & Drugs Listed Page

Profile
Issue Size --
Profile
Price Range 1026  to  1080 per share
Profile
Min Investment ₹1080
Profile
Lot Size 1
Profile
Face Value ₹1
Profile
Draft Prospectus
Invest Before the IPO Goes Live

Buy unlisted shares early and participate in the growth before public listing.

Profile
  • Basic Info
  • IPO Tentative Timetable
  • IPO Lot Size
  • Subscription Status
  • Financials
  • Profit & Loss
  • Balance Sheet
  • Cash Flow
  • Ratios
  • Growth Rates
  • Other info

Overview

Mankind Pharma Limited is a leading pharmaceutical company in India that specializes in the development, manufacturing, and marketing of high-quality generic medicines, over-the-counter products, and healthcare products. The company was founded in 1995 by R.C. Juneja and has since grown to become the 6th largest pharmaceutical company in India. Mankind Pharma has a presence in over 34 countries and has a diverse product portfolio that includes medicines for respiratory, cardiovascular, gastrointestinal, and other health conditions. The company has a strong focus on research and development and has invested in developing new products and technologies. Mankind Pharma is committed to providing affordable and accessible healthcare solutions and has received several awards and recognitions for its contribution to the pharmaceutical industry. Read More

Basic Info

Face Value 1 per share

Price 1026  to  1080 per share

P/E (x) 21.9

Sales( Cr.) 12207

PAT( Cr.) 2007

EPS 49.3

Draft Prospectus

Exchange BSE-NSE

Promoter

Company Promoters

Ramesh Juneja Rajeev Juneja Sheetal Arora Ramesh Juneja Family Trust

Pre Issue Share Holding 100%

Post Issue Share Holding --%

Listing Details:

Listing Price: 1300

Listing Gain: 16.92%

Current Price: 2375.6

Gain On Issue: 2375.6 | 0%

GMP: --

GMP %: -- %

IPO Tentative Timetable

Opening Date Apr 25, 2023
Closing Date Apr 27, 2023
Allotment Apr 28, 2023
Refund May 01, 2023
Delivery of Shares May 01, 2023
Listing Date May 02, 2023

IPO Lot Size

Application Lots Shares Amount
Retail (Min) 1 13 14,040
Retail (Max) 14 182 196,560
S-HNI (Min) 15 195 210,600
S-HNI (Max) 71 923 996,840
B-HNI (Min) 72 936 1,010,880

Objective of the Issue

1. Carry out the Offer for Sale of 4,00,58,844 Equity Shares by the Selling Shareholders aggregating to ₹ 4,326.36 Cr. 2. Achieve the benefits of listing the Equity Shares on the Stock Exchanges.

Issue

Category Nos Bid Bid (x)
QIB 20029422 984646386 49.2x
NII 6008827 22833543 3.8x
Retail 14020595 12898947 0.9x
EMP 0 0 0x
Total 40058844 613701490 15.3x

Net Sales (in cr.)

Total Income (in cr.)

Operating Profit (in cr.)

Net Profit (in cr.)

Shareholder Funds (in cr.)

Total Assets (in cr.)

Mankind Pharma Profit & Loss

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
Net Sales 3323 3944 4382 4921 4980 5872 6214 7782 8749 10260 12207
Other Income 76 71 89 72 53 104 171 196 129 280 537
Total Income 3399 4015 4471 4993 5033 5976 6385 7978 8878 10541 12744
Total Expenditure 2738 3185 3531 3927 4055 4427 4565 5791 6848 7745 9187
Operating Profit 662 830 940 1066 978 1548 1820 2187 2030 2795 3557
Interest 2 3 4 25 44 23 21 60 46 34 432
Depreciation 39 43 31 46 69 99 119 167 326 378 621
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 621 784 906 995 875 1438 1692 1975 1671 2398 2516
Provision for Tax 177 244 290 323 264 382 399 522 362 457 510
Profit After Tax 444 540 616 672 610 1056 1293 1453 1310 1941 2007
Adjustments -5 2 13 -15 -32 -26 -28 -19 -28 -28 -16
Profit After Adjustments 439 542 629 656 579 1030 1265 1433 1282 1913 1991
Adjusted Earnings Per Share 11 13.5 15.7 16.4 14.4 25.7 31.6 35.8 32 47.8 48.3

Mankind Pharma Balance Sheet

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Shareholder's Funds 2055 2257 2927 2881 2823 3485 4722 6155 7435 9363 14332
Minority's Interest 16 29 98 134 159 186 141 161 188 213 236
Borrowings 0 2 3 3 25 58 58 49 23 25 5526
Other Non-Current Liabilities 28 32 51 46 53 45 50 119 176 162 1894
Total Current Liabilities 433 528 663 1296 1024 1251 1353 2623 1863 2120 5664
Total Liabilities 2532 2848 3741 4360 4084 5025 6324 9108 9686 11883 27652
Fixed Assets 277 447 793 1014 1399 1594 1659 3583 4245 4540 19004
Other Non-Current Assets 582 695 879 773 686 609 758 1119 1113 775 1659
Total Current Assets 1673 1707 2069 2574 1943 2820 3880 4404 4325 6566 6986
Total Assets 2532 2848 3741 4360 4084 5025 6324 9108 9686 11883 27652

Mankind Pharma Cash Flow

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Opening Cash & Cash Equivalents 98 53 82 89 136 116 220 127 283 305 382
Cash Flow from Operating Activities 280 537 628 639 600 1072 1137 920 1813 2152 2413
Cash Flow from Investing Activities -348 -152 -625 -505 -444 -439 -1222 -1369 -1054 -2082 -12683
Cash Flow from Financing Activities 9 -361 2 -89 -175 -527 -8 605 -740 5 10233
Net Cash Inflow / Outflow -59 25 5 46 -19 106 -93 155 19 76 -37
Closing Cash & Cash Equivalent 39 78 87 135 116 226 127 283 305 382 404

Mankind Pharma Ratios

# Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Earnings Per Share (Rs) 10.97 13.53 15.71 16.39 14.44 25.72 31.59 35.78 32 47.75 48.25
CEPS(Rs) 12.05 14.57 16.14 17.91 16.96 28.84 35.25 40.43 40.83 57.89 63.69
DPS(Rs) 0 15 0 4.35 4.45 3.1 0 0 0 0 0
Book NAV/Share(Rs) 51.29 56.34 73.07 71.92 70.47 87 117.88 153.65 185.61 233.15 346.31
Core EBITDA Margin(%) 17.56 19.12 19.26 20.15 18.57 23.68 25.5 24.66 20.89 23.56 23.82
EBIT Margin(%) 18.68 19.81 20.58 20.68 18.45 23.95 26.49 25.21 18.86 22.78 23.25
Pre Tax Margin(%) 18.62 19.74 20.5 20.17 17.56 23.57 26.16 24.47 18.35 22.46 19.85
PAT Margin (%) 13.32 13.6 13.94 13.62 12.26 17.31 20 18 14.38 18.18 15.83
Cash Profit Margin (%) 14.47 14.7 14.64 14.55 13.64 18.94 21.84 20.07 17.96 21.72 20.73
ROA(%) 17.54 20.08 18.69 16.58 14.46 23.19 22.79 18.83 13.94 18 10.15
ROE(%) 21.61 25.06 23.76 23.13 21.41 33.48 31.51 26.72 19.27 23.14 16.98
ROCE(%) 30.32 36.47 34.98 32.75 28.8 43.57 39.97 33.96 23.49 28.35 18.32
Receivable days 21.57 17.91 14.83 17.14 18.94 22.48 24.32 16.25 19.33 24.35 34.35
Inventory Days 65.27 55.86 58.15 58.39 59.01 51.46 58.78 66.57 65.31 52.16 52.5
Payable days 99.58 94.07 104.83 124.64 128.4 127.01 144.73 131.38 130.57 101.86 99.93
PER(x) 0 0 0 0 0 0 0 0 0 48.11 50.22
Price/Book(x) 0 0 0 0 0 0 0 0 0 9.85 7
Dividend Yield(%) 0 0 0 0 0 0 0 0 0 0 0
EV/Net Sales(x) -0.01 -0.02 -0.03 0.06 0.03 -0.04 -0.07 0.06 -0.03 8.92 8.82
EV/Core EBITDA(x) -0.03 -0.08 -0.12 0.29 0.17 -0.16 -0.23 0.23 -0.12 32.74 30.28
Net Sales Growth(%) 0 18.67 11.12 12.29 1.2 17.91 5.83 25.22 12.44 17.27 18.98
EBIT Growth(%) 0 26.28 15.58 12.17 -9.91 59 17.23 18.78 -15.6 41.65 21.22
PAT Growth(%) 0 21.66 14.01 9.08 -9.13 73 22.43 12.37 -9.86 48.19 3.39
EPS Growth(%) 0 23.38 16.07 4.34 -11.88 78.11 22.81 13.28 -10.58 49.22 1.05
Debt/Equity(x) 0 0 0 0.14 0.1 0.04 0.05 0.14 0.02 0.02 0.58
Current Ratio(x) 3.86 3.24 3.12 1.99 1.9 2.25 2.87 1.68 2.32 3.1 1.23
Quick Ratio(x) 2.48 2.1 1.97 1.39 1.1 1.54 2.05 1.01 1.52 2.36 0.86
Interest Cover(x) 289.38 289.77 249.67 40.44 20.77 62.87 80.96 34.02 37.52 71.03 6.83
Total Debt/Mcap(x) 0 0 0 0 0 0 0 0 0 0 0.08

Sihora Industries Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 19% 16% 16% 14%
Operating Profit CAGR 27% 18% 18% 18%
PAT CAGR 3% 11% 14% 16%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR -4% 20% NA% NA%
ROE Average 17% 20% 24% 24%
ROCE Average 18% 23% 29% 32%

Company Contact Information

Mankind Pharma Ltd.

208 Okhla Industrial Estate Phase - 111

IPO Lead Manager(s)

Mankind Pharma Ltd.

Axis Capital Ltd.

IIFL Securities Ltd.

Jefferies India Pvt Ltd.

JP Morgan India Pvt Ltd

Kotak Mahindra Capital Co Ltd

Registrar Info

Mankind Pharma Ltd.

Frequently Asked Questions

All You Need To Know About IPO

When you leave without vesting, generally unvested ESOPs are cancelled. Vested ESOPs usually can be exercised after you depart, often within 3 to 6 months, depending on the company's ESOP plan.

For companies listed on a stock exchange, you can sell the shares any time after you exercise the ESOP option and the shares are in your demat account. If the company is unlisted or otherwise a startup, you can only sell the shares if and when the company announces a buyback or has a process for secondary sales.

Whenever you exercised your options to hold shares, you entered into a market risk situation, and if the valuation of the company drops, so do the shares.

Yes. ESOPs are valuable to the employer in that the employer is able to retain the best talent, align employee interests with company goals, and preserve cash while rewarding performance.

Wealth Icon
Don’t Miss Out on Unlisted Shares

Open your account today and gain instant access to top unlisted shares and pre-IPO opportunities.

whatsapp

Error!